• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Nuedexta

Background

Pseudobulbar Affect (PBA), a common symptom of several neurological conditions including ALS/MND. PBA is caused by damage to the nerve cells in the brain that control emotions. People affected by PBA experience sudden episodes of unintentional or involuntary crying and laughter without any emotional stimulus. The symptoms can cause embarrassment and it can disrupt daily life.

Nuedexta is an oral medication manufactured by Avanir Pharmaceuticals. After its approval in the US in 2010, Nuedexta received approval from the European Medicine Agency (EMA) but for commercial reasons, its approval was later withdrawn

Approved in:   Commercial Name: 
USA Nuedexta

How it Works

Nuedexta contains two active ingredients: dextromethorphan hydrobromide (DMX; the active ingredient in cough syrup) and quinidine sulfate. The drug acts on several different proteins throughout the body, and it is unclear exactly how it works to treat PBA. The quinidine component acts to increase the amount of DMX the body can use, but on its own, quinidine may also have beneficial effects that have not yet been discovered (Smith, 2006).

The dextromethorphan component is thought to activate certain cell receptors, such as sigma-1 receptors, which are critical for activating nerve cells. It may also inhibit receptors that suppress nerve cell activity, such as NMDA receptors. However, it is unclear how these two effects work together to reduce PBA symptoms in people with ALS/MND.

Although scientists do not know exactly how the drug works, Nuedexta has shown efficacy for treating PBA in multiple clinical trials (Ballard et al, 2015; Metman et al, 1998). Since then, researchers have investigated Nuedexta’s potential as a treatment for other motor symptoms such as impaired speech and swallowing.

Nuedexta in Clinical Trials

Nuedexta has undergone several several clinical trials, ultimately leading to US Food and Drug Administration (FDA) approval in 2010.

Study 1:

In the first pivotal clinical trial for Nuedexta, 140 people with ALS/MND and PBA were randomly assigned to one of three groups. Participants in one group received Nuedexta, while the others received either 30 mg of dextromethorphan or 30 mg of quinidine.

The drug was administered twice daily for 28 days and researchers measured peoples’ emotional outbursts on a scale from 7 (no symptoms) to 35 (many symptoms). If someone scores higher than 13 points, they receive a diagnosis of PBA.

In the trial, the people taking Nuedexta experienced lower rates of PBA episodes. They scored an average of 3.5 points lower on the symptom scale than those taking either dextromethorphan or quinidine alone. Participants taking Nuedexta also rated their quality of life and quality of relationships higher than those in the other two groups.

This trial was published in 2004  (Brooks et al, 2004).

Study 2:

In a second clinical trial, researchers compared two different compositions of Nuedexta. A total of 283 people with ALS/MND and PBA were assigned to one of three groups: Nuedexta containing 30 mg of DMX, Nuedextra containing 20 mg of DMX, or placebo. The treatments were administered twice daily for 12 weeks.

After the 12 weeks, participants receiving both compositions of Nuedexta cut PBA episodes by almost half compared to the placebo group. Furthermore, both compositions led symptoms scores to drop by 8.2 points on average, compared to placebo, which only led to a 5.7-point drop. Symptoms were more likely to go away in those who received Nuedexa, and the higher dose led to improved social functioning and mental health.

These results were published in 2010 (Pioro et al, 2010).

Dose and Administration

In its FDA-approved form, one capsule of Nuedexta contains 20 mg of dextromethorphan and 10 mg of quinidine. For treatment of PBA, people take Nuedexta once daily for seven days and then twice daily thereafter.

Reported Side Effects of Nuedexta

Nuedexta is a prescription medication that should be used in consultation with a physician. Common side effects can include diarrhea, dizziness, coughing, vomiting, fatigue, and urinary tract infections. In addition, there are reports of various drug interactions.

Do not take Nuedexta if you are taking MAO inhibitor drugs (e.g. Marplan, Parnate). Individuals with a medical history of certain disorders such as hepatitis, bone marrow depression, or thrombocytopenia may be more likely to experience complications in response to this medication. Therefore, people with ALS/MND should disclose their medical history and other medications to their healthcare team before using Nuedexta.

Current Status

Recently, Nuedexta gained attention for its potential benefits in treating other bulbar symptoms in ALS/MND, such as speech and swallowing impairments.

In 2017, researchers recruited 60 people with ALS/MND for a randomized, double-blind, cross-over clinical trial looking at if the drug could improve speech and swallowing and reduce drooling. People received Nuedexta or a placebo for 28 days then went off the drug for two weeks. Participants then switched treatment groups for another 28 days: the Nuedexta group switched to placebo and the placebo group switched to Nuedexta (Smith et al, 2017). The clinical trial showed promising results, but more research is warranted.

ALSUntangled have also reviewed the potneital of Nuedexta for treating PBA and off-label use of Nuedexta for improving bulbar function in ALS and state they support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA (ALSUntangled  #71, 2023).

While clinical trials have shown promising results, Nuedexta is still only approved for the treatment of PBA, and only in the United States.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: Consult with your doctor to determine if Nuedexta is an option for you. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines currently being used. Your doctor will determine the right plan for your needs.

The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Approved Drugs

  • Nuedexta
  • Radicava/Edaravone
  • Riluzole/Tiglutik
  • Rozebalamin / Methylcobalamin
  • Tofersen/Qalsody

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Bob Simonds, USA

    Bob Simonds, USA

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Jon Newsome, USA

    Jon Newsome, USA

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Frank Taylor, USA

    Frank Taylor, USA

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • David Solomon, UK

    David Solomon, UK

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Ali Var, Turkey

    Ali Var, Turkey

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Jean Waters, UK

    Jean Waters, UK

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Olga, Argentina

    Olga, Argentina

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Mike Cels, Canada

    Mike Cels, Canada

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • Liam Dwyer, England

    Liam Dwyer, England

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Christian Bär, Germany

    Christian Bär, Germany

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Timmy, Belgium

    Timmy, Belgium

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login